Sugi Predict

Sugi Predict / Compounds / SCHEMBL4780564

SCHEMBL4780564

SCHEMBL4780564

COc1cc(NS(=O)(=O)c2cccc(C(F)(F)F)c2)c(-c2nc(C)no2)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 1/20 0.47
▸ SLC40A1 Q9NP59 1/20 0.46
▸ MEN1 O00255 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ GAA P10253 2/20 0.45
▸ MAPT P10636 1/20 0.44
▸ KAT7 O95251 1/20 0.44
▸ KAT6A Q92794 1/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ SCN9A Q15858 5/20 0.43
▸ CLK1 P49759 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ CYP2C9 P11712 2/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ HSD17B2 P37059 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30304724 1.00 AXL (0.47) AXLSLC40A1MEN1KMT2AGAA
SCHEMBL4846633 0.88 SLC20A2 (0.49) AXLSLC40A1MEN1KMT2AGAA
SCHEMBL4775594 0.88 SLC20A2 (0.51) AXLSLC40A1MEN1KMT2AGAA
SCHEMBL4836640 0.87 EDNRA (0.46) SLC40A1MEN1KMT2AMAPTLMNA
SCHEMBL4781223 0.85 EDNRB (0.48) SLC40A1MEN1KMT2AMAPTNPSR1
SCHEMBL4726823 0.85 MEN1 (0.55) SLC40A1MEN1KMT2AGAANPSR1
SCHEMBL31478890 0.85 MEN1 (0.55) SLC40A1MEN1KMT2AGAANPSR1
SCHEMBL4777459 0.84 LMNA (0.45) SLC40A1MEN1KMT2AGAAMAPT
SCHEMBL4781870 0.83 PIK3CG (0.40) MEN1KMT2ALMNASCN9ASMN1; SMN2
SCHEMBL4781581 0.83 AXL (0.49) AXLSLC40A1MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115943138-A Compositions comprising GARDOS channel antagonists and uses thereof 阿迪玛生物有限责任公司 2023-04-07 — — CN claimed
US-20180136227-A1 Treatment and Diagnosis of Hereditary Xerocytosis CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-05-17 — — US claimed
EP-3106155-A1 TREATMENT AND DIAGNOSIS OF HEREDITARY XEROCYTOSIS Universite d'Aix Marseille (FR) 2016-12-21 — — EP claimed
WO-2023069529-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS AKIRABIO, INC. (US) 2023-04-27 — — WO disclosed
US-20230123277-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE AND THALASSEMIA AKIRABIO INC (US) 2023-04-20 — — US disclosed
US-20230055298-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS ADIMABIO LLC 2023-02-23 — — US disclosed
WO-2021211890-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS ADIMABIO LLC (US) 2021-10-21 — — WO disclosed
US-20180136227-A1 Treatment and Diagnosis of Hereditary Xerocytosis CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-05-17 — — US disclosed
EP-3307252-A1 TREATMENT AND DIAGNOSIS OF HEREDITARY XEROCYTOSIS Universite d'Aix Marseille (FR) 2018-04-18 — — EP disclosed
WO-2016202854-A1 TREATMENT AND DIAGNOSIS OF HEREDITARY XEROCYTOSIS UNIVERSITE D'AIX-MARSEILLE (FR) 2016-12-22 — — WO disclosed
EP-3106155-A1 TREATMENT AND DIAGNOSIS OF HEREDITARY XEROCYTOSIS Universite d'Aix Marseille (FR) 2016-12-21 — — EP disclosed
WO-2008008374-A2 CCR2 INHIBITORS AND METHODS OF USE THEREOF CHEMOCENTRYX, INC. (US) 2008-01-17 — — WO disclosed
US-20070004784-A1 Sulfonamides as potassium channel blockers ICAGEN, INC. (US) 2007-01-04 — — US disclosed
US-20070004784-A1 Sulfonamides as potassium channel blockers ICAGEN, INC. (US) 2007-01-04 — — US disclosed
US-7119112-B2 Sulfonamides as potassium channel blockers ICAGEN, INC. (US) 2006-10-10 — — US disclosed
US-20060094721-A9 Sulfonamides as potassium channel blockers ICAGEN, INC. (US) 2006-05-04 — — US disclosed
US-20040106613-A1 Sulfonamides as potassium channel blockers ICAGEN, INC. 2004-06-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094721-A9 Sulfonamides as potassium channel blockers KCNJ2, KCNJ1, KCNJ11 AXL 4423/4885SLC40A1 1178/4885MEN1 2417/4885
US-20040106613-A1 Sulfonamides as potassium channel blockers KCNJ2, KCNJ1, KCNJ11 AXL 4423/4885SLC40A1 1178/4885MEN1 2417/4885
US-20230055298-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS TYMP, HBZ, HBB AXL 1171/4885SLC40A1 376/4885MEN1 3869/4885
US-20230123277-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE AND THALASSEMIA HBB, HBZ, TYMP AXL 1672/4885SLC40A1 241/4885MEN1 4512/4885
US-20070004784-A1 Sulfonamides as potassium channel blockers KCNJ2, KCNJ1, KCNJ11 AXL 4423/4885SLC40A1 1178/4885MEN1 2417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.